EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE
Clinical trials for EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients in japan?
Disease control OngoingThis study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …
Matched conditions: EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients
Disease control OngoingThis study tests an experimental drug called IMC-001 in 23 adults with a rare lymphoma (NK/T-cell) that has returned or stopped responding to prior therapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive IMC-001 and are monito…
Matched conditions: EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE
Phase: PHASE2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to cut relapse in rare lymphoma
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding the drug tislelizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage NK/T-cell lymphoma, a rare blood cancer. About 60 adults aged 18 to 70 will receive the combination treatment. The goal is to see if this …
Matched conditions: EXTRANODAL NK/T CELL LYMPHOMA, NASAL TYPE
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC